These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 34044875)

  • 41. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer's Disease.
    Galasko D; Farlow MR; Lucey BP; Honig LS; Elbert D; Bateman R; Momper J; Thomas R; Rissman RA; Pa J; Aslanyan V; Balasubramanian A; West T; Maccecchini M; Feldman HH
    medRxiv; 2024 Mar; ():. PubMed ID: 38562783
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An exploratory clinical study of p38
    Scheltens P; Prins N; Lammertsma A; Yaqub M; Gouw A; Wink AM; Chu HM; van Berckel BNM; Alam J
    Ann Clin Transl Neurol; 2018 Apr; 5(4):464-473. PubMed ID: 29687023
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.
    Wessels AM; Tariot PN; Zimmer JA; Selzler KJ; Bragg SM; Andersen SW; Landry J; Krull JH; Downing AM; Willis BA; Shcherbinin S; Mullen J; Barker P; Schumi J; Shering C; Matthews BR; Stern RA; Vellas B; Cohen S; MacSweeney E; Boada M; Sims JR
    JAMA Neurol; 2020 Feb; 77(2):199-209. PubMed ID: 31764959
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial.
    Abdullah L; Crawford F; Tsolaki M; Börjesson-Hanson A; Olde Rikkert M; Pasquier F; Wallin A; Kennelly S; Ait-Ghezala G; Paris D; Hendrix S; Blennow K; Lawlor B; Mullan M
    Front Neurol; 2020; 11():149. PubMed ID: 32210906
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial.
    Pontecorvo MJ; Lu M; Burnham SC; Schade AE; Dage JL; Shcherbinin S; Collins EC; Sims JR; Mintun MA
    JAMA Neurol; 2022 Dec; 79(12):1250-1259. PubMed ID: 36251300
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial.
    Teng E; Manser PT; Pickthorn K; Brunstein F; Blendstrup M; Sanabria Bohorquez S; Wildsmith KR; Toth B; Dolton M; Ramakrishnan V; Bobbala A; Sikkes SAM; Ward M; Fuji RN; Kerchner GA;
    JAMA Neurol; 2022 Aug; 79(8):758-767. PubMed ID: 35696185
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
    Fujino T; Yamada T; Asada T; Tsuboi Y; Wakana C; Mawatari S; Kono S
    EBioMedicine; 2017 Mar; 17():199-205. PubMed ID: 28259590
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease.
    Nygaard HB; Wagner AF; Bowen GS; Good SP; MacAvoy MG; Strittmatter KA; Kaufman AC; Rosenberg BJ; Sekine-Konno T; Varma P; Chen K; Koleske AJ; Reiman EM; Strittmatter SM; van Dyck CH
    Alzheimers Res Ther; 2015; 7(1):35. PubMed ID: 25874001
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
    Ostrowitzki S; Lasser RA; Dorflinger E; Scheltens P; Barkhof F; Nikolcheva T; Ashford E; Retout S; Hofmann C; Delmar P; Klein G; Andjelkovic M; Dubois B; Boada M; Blennow K; Santarelli L; Fontoura P;
    Alzheimers Res Ther; 2017 Dec; 9(1):95. PubMed ID: 29221491
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency: A Randomized Clinical Trial.
    Ljubenkov PA; Edwards L; Iaccarino L; La Joie R; Rojas JC; Koestler M; Harris B; Boeve BF; Borroni B; van Swieten JC; Grossman M; Pasquier F; Frisoni GB; Mummery CJ; Vandenberghe R; Le Ber I; Hannequin D; McGinnis SM; Auriacombe S; Onofrj M; Goodman IJ; Riordan HJ; Wisniewski G; Hesterman J; Marek K; Haynes BA; Patzke H; Koenig G; Hilt D; Moebius H; Boxer AL
    JAMA Netw Open; 2021 Sep; 4(9):e2125584. PubMed ID: 34559230
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease.
    Tarawneh R; D'Angelo G; Crimmins D; Herries E; Griest T; Fagan AM; Zipfel GJ; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2016 May; 73(5):561-71. PubMed ID: 27018940
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
    Coric V; van Dyck CH; Salloway S; Andreasen N; Brody M; Richter RW; Soininen H; Thein S; Shiovitz T; Pilcher G; Colby S; Rollin L; Dockens R; Pachai C; Portelius E; Andreasson U; Blennow K; Soares H; Albright C; Feldman HH; Berman RM
    Arch Neurol; 2012 Nov; 69(11):1430-40. PubMed ID: 22892585
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study.
    Novak G; Streffer JR; Timmers M; Henley D; Brashear HR; Bogert J; Russu A; Janssens L; Tesseur I; Tritsmans L; Van Nueten L; Engelborghs S
    Alzheimers Res Ther; 2020 May; 12(1):58. PubMed ID: 32410694
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease.
    Schwam EM; Nicholas T; Chew R; Billing CB; Davidson W; Ambrose D; Altstiel LD
    Curr Alzheimer Res; 2014; 11(5):413-21. PubMed ID: 24801218
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial.
    Rosenberg PB; Lanctôt KL; Drye LT; Herrmann N; Scherer RW; Bachman DL; Mintzer JE; ADMET Investigators
    J Clin Psychiatry; 2013 Aug; 74(8):810-6. PubMed ID: 24021498
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial.
    Craft S; Claxton A; Baker LD; Hanson AJ; Cholerton B; Trittschuh EH; Dahl D; Caulder E; Neth B; Montine TJ; Jung Y; Maldjian J; Whitlow C; Friedman S
    J Alzheimers Dis; 2017; 57(4):1325-1334. PubMed ID: 28372335
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial.
    Vossel K; Ranasinghe KG; Beagle AJ; La A; Ah Pook K; Castro M; Mizuiri D; Honma SM; Venkateswaran N; Koestler M; Zhang W; Mucke L; Howell MJ; Possin KL; Kramer JH; Boxer AL; Miller BL; Nagarajan SS; Kirsch HE
    JAMA Neurol; 2021 Nov; 78(11):1345-1354. PubMed ID: 34570177
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CSF Aβ
    Rizzi L; Missiaggia L; Roriz-Cruz M
    Neuromolecular Med; 2018 Dec; 20(4):491-497. PubMed ID: 30306396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.